Table 1.
Baseline characteristics of the study population by eGFR category
| eGFR, mL/min/1.73 m2 | ||||
|---|---|---|---|---|
| ≥90 (n = 27 556) | 60 to <90 (n = 18 866) | <60 (n = 2096) | Total (n = 48 518) | |
| Age, years | 46.7 (10.6) | 56.8 (10.9) | 64.6 (12.1) | 51.4 (12.1) |
| 0–44, n (%) | 12 011 (43.6) | 2588 (13.7) | 139 (6.6) | 14 738 (30.4) |
| 45–54, n (%) | 9129 (33.1) | 5113 (27.1) | 267 (12.7) | 14 509 (29.9) |
| 55–64, n (%) | 5014 (18.2) | 6434 (34.1) | 546 (26.0) | 11 994 (24.7) |
| 65+, n (%) | 1402 (5.1) | 4731 (25.1) | 1144 (54.6) | 7277 (15.0) |
| Men, n (%) | 14 613 (53.0) | 8201 (43.5) | 968 (46.2) | 23 782 (49.0) |
| BMI, kg/m2 | 26.5 (4.5) | 28.1 (4.8) | 28.9 (5.1) | 27.2 (4.7) |
| 30+, n (%) | 5146 (18.7) | 5599 (29.7) | 783 (37.4) | 11 528 (23.8) |
| Smoking, n (%) | 8660 (31.4) | 4787 (25.4) | 437 (20.8) | 13 884 (28.6) |
| Hypertension, n (%) | 9820 (35.6) | 11 092 (58.8) | 1608 (76.7) | 22 520 (46.4) |
| History of diabetes, n (%) | 863 (3.1) | 1093 (5.8) | 275 (13.1) | 2231 (4.6) |
| SBP, mmHg | 131.6 (18.7) | 141.5 (21.4) | 149.9 (23.8) | 136.2 (20.8) |
| Total cholesterol, mmol/L | 5.8 (1.2) | 5.8 (1.2) | 5.7 (1.3) | 5.8 (1.2) |
| Creatinine, mg/dL | 0.8 (0.1) | 0.9 (0.2) | 1.5 (0.9) | 0.8 (0.3) |
| Cystatin C, mg/L | 0.8 (0.1) | 1.0 (0.1) | 1.4 (0.5) | 0.9 (0.2) |
| eGFR, mL/min/1.73 m2 | 108.4 (15.4) | 78.6 (7.8) | 49.9 (9.0) | 94.3 (21.4) |
| hs‐CRP, mg/L | 1.1 [0.5, 2.3] | 1.7 [0.9, 3.5] | 2.6 [1.3, 5.5] | 1.4 [0.7, 2.9] |
| hs‐cTnI, ng/L | 2.1 [1.3, 3.8] | 2.8 [1.8, 4.5] | 4.7 [3.0, 7.3] | 2.5 [1.5, 4.3] |
| NT‐proBNP, ng/L | 36.7 [17.9, 67.7] | 56.3 [27.9, 106.2] | 114.8 [54.3, 241.6] | 44.8 [21.8, 85.7] |
Baseline characteristics of the pooled study cohorts are presented as absolute and relative frequencies for categorical variables and means (standard deviations) or medians [25th, 75th percentiles] for continuous variables. BMI, body mass index; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐cTnI, high‐sensitivity cardiac troponin I; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide.